Opus Genetics (IRD) Free Cash Flow Growth (3y) (2013 - 2026)
Opus Genetics (IRD) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 45.09% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.85% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -4.45% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 80.69% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 8.92% |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -141.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141.49% |
| Mar 31, 2026 | -51.69% |
| Dec 31, 2025 | -32.79% |
| Sep 30, 2025 | -11.03% |
| Jun 30, 2025 | -39.18% |
| Mar 31, 2025 | -13.39% |
| Dec 31, 2024 | -9.62% |
| Sep 30, 2024 | -12.70% |
| Jun 30, 2024 | -18.99% |
| Mar 31, 2024 | 0.55% |
| Dec 31, 2023 | 44.92% |
| Sep 30, 2023 | -41.68% |
| Jun 30, 2023 | 52.11% |
| Mar 31, 2023 | -70.78% |
| Dec 31, 2022 | 79.65% |
| Sep 30, 2022 | -23.67% |
| Jun 30, 2022 | -28.08% |
| Mar 31, 2022 | -11.99% |
| Dec 31, 2021 | -6.91% |
| Sep 30, 2021 | 5.17% |